接受经皮冠状动脉介入治疗患者的脂蛋白(a)与冠状动脉疾病预后的相关性

IF 0.9 4区 医学
Texas Heart Institute Journal Pub Date : 2024-12-17 eCollection Date: 2024-07-01 DOI:10.14503/THIJ-23-8372
Azhi ShaMa, Chunlan Ma, Yingying Huang, Jingyue Hu, Chunmei Xu, Zhuxin Li, Jing Wang, Chunyu Zeng
{"title":"接受经皮冠状动脉介入治疗患者的脂蛋白(a)与冠状动脉疾病预后的相关性","authors":"Azhi ShaMa, Chunlan Ma, Yingying Huang, Jingyue Hu, Chunmei Xu, Zhuxin Li, Jing Wang, Chunyu Zeng","doi":"10.14503/THIJ-23-8372","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elevated lipoprotein(a) (Lp[a]) is a risk factor for first atherosclerotic thrombosis events, but the role of elevated Lp(a) in secondary prevention is controversial. This study aimed to retrospectively investigate the influence of elevated Lp(a) levels on the prognosis of patients with coronary artery disease.</p><p><strong>Methods: </strong>The team collected and compared clinical information of patients hospitalized during percutaneous coronary intervention (PCI). This study used a multivariate logistic regression model to evaluate the relationships between Lp(a) levels, cardiovascular risk factors, and the prognosis of coronary artery disease in patients undergoing PCI.</p><p><strong>Results: </strong>There were no statistically significant differences between patients grouped according to Lp(a) level in terms of sex; age; body mass index and obesity; hyperuricemia; smoking; cardiac insufficiency; acute myocardial infarction; multivessel lesion; in-stent restenosis; secondary PCI; apolipoprotein AI level; incidence of high total cholesterol or high low-density lipoprotein cholesterol; or family history of hypertension, diabetes, or coronary artery disease. The average Lp(a) concentration did not statistically significantly decrease after 1 year of statin treatment after PCI. One year after patients began statins, there were no significant differences between Lp(a) groups in the incidence of high triglycerides (<i>P</i> = .13), high total cholesterol (<i>P</i> = .52), or high low-density lipoprotein cholesterol (<i>P</i> = .051). Multivariate logistic regression analysis indicated that diabetes (<i>P</i> = .02) was associated with in-stent restenosis, whereas diabetes (<i>P</i> = .02) and multivessel lesions (<i>P</i> < .001) were associated with secondary PCI in patients who underwent coronary angiography 1 year after PCI. Compared with normal Lp(a) levels, high Lp(a) levels did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.</p><p><strong>Conclusion: </strong>Sustained high concentrations of Lp(a) did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"51 2","pages":"e238372"},"PeriodicalIF":0.9000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650146/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correlation Between Lipoprotein(a) and Prognosis for Coronary Artery Disease in Patients Undergoing Percutaneous Coronary Intervention.\",\"authors\":\"Azhi ShaMa, Chunlan Ma, Yingying Huang, Jingyue Hu, Chunmei Xu, Zhuxin Li, Jing Wang, Chunyu Zeng\",\"doi\":\"10.14503/THIJ-23-8372\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Elevated lipoprotein(a) (Lp[a]) is a risk factor for first atherosclerotic thrombosis events, but the role of elevated Lp(a) in secondary prevention is controversial. This study aimed to retrospectively investigate the influence of elevated Lp(a) levels on the prognosis of patients with coronary artery disease.</p><p><strong>Methods: </strong>The team collected and compared clinical information of patients hospitalized during percutaneous coronary intervention (PCI). This study used a multivariate logistic regression model to evaluate the relationships between Lp(a) levels, cardiovascular risk factors, and the prognosis of coronary artery disease in patients undergoing PCI.</p><p><strong>Results: </strong>There were no statistically significant differences between patients grouped according to Lp(a) level in terms of sex; age; body mass index and obesity; hyperuricemia; smoking; cardiac insufficiency; acute myocardial infarction; multivessel lesion; in-stent restenosis; secondary PCI; apolipoprotein AI level; incidence of high total cholesterol or high low-density lipoprotein cholesterol; or family history of hypertension, diabetes, or coronary artery disease. The average Lp(a) concentration did not statistically significantly decrease after 1 year of statin treatment after PCI. One year after patients began statins, there were no significant differences between Lp(a) groups in the incidence of high triglycerides (<i>P</i> = .13), high total cholesterol (<i>P</i> = .52), or high low-density lipoprotein cholesterol (<i>P</i> = .051). Multivariate logistic regression analysis indicated that diabetes (<i>P</i> = .02) was associated with in-stent restenosis, whereas diabetes (<i>P</i> = .02) and multivessel lesions (<i>P</i> < .001) were associated with secondary PCI in patients who underwent coronary angiography 1 year after PCI. Compared with normal Lp(a) levels, high Lp(a) levels did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.</p><p><strong>Conclusion: </strong>Sustained high concentrations of Lp(a) did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.</p>\",\"PeriodicalId\":48680,\"journal\":{\"name\":\"Texas Heart Institute Journal\",\"volume\":\"51 2\",\"pages\":\"e238372\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650146/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Texas Heart Institute Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14503/THIJ-23-8372\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Texas Heart Institute Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14503/THIJ-23-8372","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:脂蛋白(a)升高(Lp[a])是首次动脉粥样硬化性血栓事件的危险因素,但脂蛋白(a)升高在二级预防中的作用存在争议。本研究旨在回顾性探讨Lp(a)水平升高对冠状动脉疾病患者预后的影响。方法:收集并比较经皮冠状动脉介入治疗(PCI)住院患者的临床资料。本研究采用多变量logistic回归模型评价行PCI患者Lp(a)水平、心血管危险因素与冠状动脉疾病预后之间的关系。结果:按Lp(a)水平分组的患者在性别上差异无统计学意义;年龄;体重指数与肥胖;高尿酸血;吸烟;心功能不全;急性心肌梗死;多支病变;支架内再狭窄;二次PCI;载脂蛋白AI水平;高总胆固醇或高低密度脂蛋白胆固醇的发生率;或有高血压、糖尿病或冠状动脉疾病的家族史。PCI术后他汀类药物治疗1年后,平均Lp(a)浓度无统计学意义。在患者开始使用他汀类药物一年后,Lp(a)组在高甘油三酯(P = 0.13)、高总胆固醇(P = 0.52)或高低密度脂蛋白胆固醇(P = 0.051)的发生率方面没有显著差异。多因素logistic回归分析显示,糖尿病(P = 0.02)与支架内再狭窄相关,而糖尿病(P = 0.02)和多血管病变(P < 0.001)与PCI术后1年行冠状动脉造影患者的二次PCI相关。与正常Lp(a)水平相比,高Lp(a)水平并未显著增加PCI术后1年冠脉造影患者支架内再狭窄或二次PCI的发生率。结论:持续高浓度的Lp(a)不会显著增加冠脉造影后1年冠脉造影患者支架内再狭窄或二次PCI的发生率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Correlation Between Lipoprotein(a) and Prognosis for Coronary Artery Disease in Patients Undergoing Percutaneous Coronary Intervention.

Background: Elevated lipoprotein(a) (Lp[a]) is a risk factor for first atherosclerotic thrombosis events, but the role of elevated Lp(a) in secondary prevention is controversial. This study aimed to retrospectively investigate the influence of elevated Lp(a) levels on the prognosis of patients with coronary artery disease.

Methods: The team collected and compared clinical information of patients hospitalized during percutaneous coronary intervention (PCI). This study used a multivariate logistic regression model to evaluate the relationships between Lp(a) levels, cardiovascular risk factors, and the prognosis of coronary artery disease in patients undergoing PCI.

Results: There were no statistically significant differences between patients grouped according to Lp(a) level in terms of sex; age; body mass index and obesity; hyperuricemia; smoking; cardiac insufficiency; acute myocardial infarction; multivessel lesion; in-stent restenosis; secondary PCI; apolipoprotein AI level; incidence of high total cholesterol or high low-density lipoprotein cholesterol; or family history of hypertension, diabetes, or coronary artery disease. The average Lp(a) concentration did not statistically significantly decrease after 1 year of statin treatment after PCI. One year after patients began statins, there were no significant differences between Lp(a) groups in the incidence of high triglycerides (P = .13), high total cholesterol (P = .52), or high low-density lipoprotein cholesterol (P = .051). Multivariate logistic regression analysis indicated that diabetes (P = .02) was associated with in-stent restenosis, whereas diabetes (P = .02) and multivessel lesions (P < .001) were associated with secondary PCI in patients who underwent coronary angiography 1 year after PCI. Compared with normal Lp(a) levels, high Lp(a) levels did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.

Conclusion: Sustained high concentrations of Lp(a) did not significantly increase the incidence of in-stent restenosis or secondary PCI in patients who underwent coronary angiography 1 year after PCI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Texas Heart Institute Journal
Texas Heart Institute Journal CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
11.10%
发文量
131
期刊介绍: For more than 45 years, the Texas Heart Institute Journal has been published by the Texas Heart Institute as part of its medical education program. Our bimonthly peer-reviewed journal enjoys a global audience of physicians, scientists, and healthcare professionals who are contributing to the prevention, diagnosis, and treatment of cardiovascular disease. The Journal was printed under the name of Cardiovascular Diseases from 1974 through 1981 (ISSN 0093-3546). The name was changed to Texas Heart Institute Journal in 1982 and was printed through 2013 (ISSN 0730-2347). In 2014, the Journal moved to online-only publication. It is indexed by Index Medicus/MEDLINE and by other indexing and abstracting services worldwide. Our full archive is available at PubMed Central. The Journal invites authors to submit these article types for review: -Clinical Investigations- Laboratory Investigations- Reviews- Techniques- Coronary Anomalies- History of Medicine- Case Reports/Case Series (Submission Fee: $70.00 USD)- Images in Cardiovascular Medicine (Submission Fee: $35.00 USD)- Guest Editorials- Peabody’s Corner- Letters to the Editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信